<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547790</url>
  </required_header>
  <id_info>
    <org_study_id>19-010612</org_study_id>
    <nct_id>NCT04547790</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Psyllium vs. Wheat Dextrin on Glycemic Control and Inflammatory Markets in Diabetes Mellitus 2</brief_title>
  <official_title>Fiber and Diabetes (FAD) Study: Effect of Psyllium vs. Wheat Dextrin on Glycemic Control and Inflammatory Markers in DM2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which of Psyllium and Wheat Dextrin is more&#xD;
      effective in lowering fasting blood sugar and hemoglobin A1c, and to evaluate the effects&#xD;
      they have on laboratory values.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fasting blood sugar</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ceramides</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Psyllium group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take psyllium once daily for the first three days, then twice daily starting Day 4 until the end of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wheat Dextrin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take wheat dextrin once daily for the first three days, then twice daily starting Day 4 until the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Psyllium</intervention_name>
    <description>One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water</description>
    <arm_group_label>Psyllium group</arm_group_label>
    <other_name>Metamucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wheat Dextrin</intervention_name>
    <description>One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water</description>
    <arm_group_label>Wheat Dextrin group</arm_group_label>
    <other_name>Benefiber</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject population: This will include adult ECH patients (18 years of age or older) with&#xD;
        DM2 who receive their care and diabetic management through Primary Care in Rochester at&#xD;
        Mayo Clinic.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  May be on oral therapy (including metformin) or insulin&#xD;
&#xD;
          -  Most recent HgbA1c level measuring between 6.5 -10 within the last 3 months&#xD;
&#xD;
          -  May be on stable (&gt; 4 weeks) statin dose or no statin therapy&#xD;
&#xD;
          -  Willing to sign informed consent and stay on current medical regimen&#xD;
&#xD;
          -  Does not use regular dietary fiber supplements; has not had any psyllium containing&#xD;
             products in the previous 30 days; is willing to refrain from taking any other fiber&#xD;
             containing supplement products during the study&#xD;
&#xD;
          -  Has not used systemic steroid agents in the last 30 days&#xD;
&#xD;
          -  Able to participate fully in all aspects of the study&#xD;
&#xD;
          -  Have access and ability to utilize text messaging or email&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling/unable to participate&#xD;
&#xD;
          -  Comorbid inflammatory bowel disease, celiac sprue, nephrotic syndrome, severe&#xD;
             cholestasis (e.g., primary biliary cirrhosis), or history of bariatric surgery/bowel&#xD;
             resection&#xD;
&#xD;
          -  Alcohol use in excess of 14 drinks/week&#xD;
&#xD;
          -  Allergic reactions to psyllium or wheat dextrin&#xD;
&#xD;
          -  Has participated in a clinical drug study or used an investigational new drug during&#xD;
             the previous 30 days&#xD;
&#xD;
          -  Self-Report of known or suspected pregnancy or immediate plans (within 3 months) of&#xD;
             becoming pregnant&#xD;
&#xD;
          -  Currently breastfeeding&#xD;
&#xD;
          -  Has a known history of any condition or factor judged by the investigator to preclude&#xD;
             participation in the study or which might hinder adherence&#xD;
&#xD;
          -  Anticipated or recent major changes in diet or exercise routine&#xD;
&#xD;
          -  Anticipated colonoscopy prep during 3 months of study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Kopecky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Ondler Hinson</last_name>
    <phone>507-293-7891</phone>
    <email>ondlerhinson.heather@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia Meek</last_name>
    <phone>507-293-7892</phone>
    <email>meek.alicia@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Stephen L. Kopecky</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

